Brief: Cognition Therapeutics Provides Regulatory Update On Zervimesine In Alzheimer’s Disease
25/06/2025 12:34
June 25 (Reuters) - Cognition Therapeutics Inc CGTX.O: COGNITION THERAPEUTICS PROVIDES REGULATORY UPDATE ON ZERVIMESINE (CT1812) IN ALZHEIMER’S DISEASE AND DEMENTIA WITH LEWY BODIES (DLB) COGNITION THERAPEUTICS INC - TO CONDUCT END-OF-PHASE 2 MEETING WITH FDA ON JULY 9, 2025 Source text: ID:nGNX2qzmb3 Further company coverage: CGTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cognition Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Cognition rises after FDA backs late-stage trial plan for dementia drug
Brief: Cognition Therapeutics Announces Issuance Of Composition Of Matter Patent, Extending Protection For Zervimesine (CT1812) Through 2045
Brief: Cognition Therapeutics Schedules A Type C Meeting With FDA To Align On Endpoints For Phase 3 Trial Of Zervimesine (Ct1812) In DLB